Trial Assessing Individualized Options for Treatment for breast cancer: the TAILORx trial

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA. Cancer J. Clin.58(2),71–96 (2008).
  MedlineGoogle Scholar
• 2  Sparano JA, Fazzari MJ, Childs G: Clinical application of molecular profiling in breast cancer. Future Oncol.1(4),485–496 (2005).
  CASGoogle Scholar
• 3  Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J. Clin. Oncol.15(4),1385–1394 (1997).
  MedlineGoogle Scholar
• 4  Fisher B, Dignam J, Wolmark N et al.: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl. Cancer Inst.89(22),1673–1682 (1997).
  Medline CASGoogle Scholar
• 5  Fisher B, Jeong JH, Dignam J et al.: Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J. Natl. Cancer Inst. Monogr. (30),62–66 (2001).
  MedlineGoogle Scholar
• 6  Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R: Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987–2000. J. Clin. Oncol.24(6),872–877 (2006).
  Medline CASGoogle Scholar
• 7  Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Clarke M, Collins R et al.: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365,1687–1717 (2005).
  MedlineGoogle Scholar
• 8  National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J. Natl. Cancer Inst. Monogr. (30),5–15 (2001).
  Google Scholar
• 9  Goldhirsch A, Coates AS, Gelber RD et al.: First--select the target: better choice of adjuvant treatments for breast cancer patients. Ann. Oncol.17(12),1772–1776 (2006).
  Medline CASGoogle Scholar
• 10  Carlson RW, Brown E, Burstein HJ et al.: NCCN Task Force Report: adjuvant therapy for breast cancer. J. Natl Compr. Canc. Netw.4(Suppl. 1),S1–S26 (2006).
  MedlineGoogle Scholar
• 11  Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol.26(5),721–728 (2008).▪ Describe the development of Oncotype DX™, a 21-gene assay for patients with estrogen-receptor (ER)-positive breast cancer and node-negative breast cancer and its use in the TAILORx trial.
  MedlineGoogle Scholar
• 12  Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351(27),2817–2826 (2004).▪ First published evidence that a multigene assay could be used to quantify the risk of distant recurrence in node-negative, tamoxifen-treated hormone-receptor-positive breast cancer.
  Medline CASGoogle Scholar
• 13  Taube SE, Jacobson JW, Lively TG: Cancer diagnostics: decision criteria for marker utilization in the clinic. Am. J. Pharmacogenomics5(6),357–364 (2005).
  MedlineGoogle Scholar
• 14  Paik S, Tang G, Shak S et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol.24(23),3726–3734 (2006).▪ First published evidence that a multigene assay could be used to predict benefit of chemotherapy in node-negative, hormone-receptor-positive breast cancer.
  Medline CASGoogle Scholar
• 15  Henderson IC, Patek AJ: The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res. Treat.52(1–3),261–288 (1998).
  Medline CASGoogle Scholar
• 16  Eifel P, Axelson JA, Costa J et al.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J. Natl. Cancer Inst.93(13),979–989 (2001).
  Medline CASGoogle Scholar
• 17  Carlson RW, Edge SB, Theriault RL: NCCN: Breast cancer. Cancer Control8(6 Suppl. 2),54–61 (2001).
  Medline CASGoogle Scholar
• 18  Goldhirsch A, Wood WC, Gelber RD et al.: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol.21(17),3357–3365 (2003).
  MedlineGoogle Scholar
• 19  Fisher B, Jeong JH, Bryant J et al.: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet364(9437),858–868 (2004).
  Medline CASGoogle Scholar
• 20  Proceedings of the 9th International Conference on Primary Therapy of Early Breast Cancer. January 26–29, 2005. St. Gallen, Switzerland. Breast14(6),427–642 (2005).
  MedlineGoogle Scholar
• 21  Sorlie T, Wang Y, Xiao C et al.: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics7,127 (2006).
  MedlineGoogle Scholar
• 22  Sorlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA100(14),8418–8423 (2003).
  Medline CASGoogle Scholar
• 23  Van de Vijver MJ, He YD, van’t Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347(25),1999–2009 (2002).
  Medline CASGoogle Scholar
• 24  Wang Y, Klijn JG, Zhang Y et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet365(9460),671–679 (2005).
  Medline CASGoogle Scholar
• 25  Liu R, Wang X, Chen GY et al.: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med.356(3),217–226 (2007).
  Medline CASGoogle Scholar
• 26  Fan C, Oh DS, Wessels L et al.: Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med.355(6),560–569 (2006).
  Medline CASGoogle Scholar
• 27  Marchionni L, Wilson RF, Wolff AC et al.: Systematic review: gene expression profiling assays in early-stage breast cancer. Ann. Intern. Med.148(5),358–369 (2008).
  MedlineGoogle Scholar
• 28  Esteva FJ, Sahin AA, Cristofanilli M et al.: Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin. Cancer Res.11(9),3315–3319 (2005).
  Medline CASGoogle Scholar
• 29  Habel L, Shak S, Jacobs MK et al.: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res.8(3),R25 (2006).▪ Large, population-based study of lymph-node-negative patients validating that the 21-gene assay was strongly associated with risk of breast cancer death among ER-positive, tamoxifen-treated and -untreated patients.
  MedlineGoogle Scholar
• 30  Lo SS, Norton J, Mumby PB et al.: Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection. J. Clin. Oncol.25 (2007 ASCO Annual Meeting Proceedings [Post-Meeting Edition]) (2007).
  Google Scholar
• 31  Kamal AH, Loprinzi CL, Reynolds C et al.: How well do standard prognostic criteria predict oncotype DX (ODX) scores? J. Clin. Oncol.25(2007 ASCO Annual Meeting Proceedings [Post-Meeting Edition]),576 (2007).
  Google Scholar
• 32  Hudis CA, Barlow WE, Costantino JP et al.: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J. Clin. Oncol.25(15),2127–2132 (2007).
  MedlineGoogle Scholar
• 33  Albain KBW, O’Malley F, Siziolpikou K et al.: Concurrent versus sequential chemohormonal therapy versus tamoxfien alone for postmenopausal, node-positive, ER and/or PgR-positive breast cancer: mature outcomes and new biologic correlates on Phase III intergroup trial 0100 (S8814). Breast Cancer Res. Treat.90,195 (2005).
  Google Scholar
• 34  Ravdin PM, Siminoff LA, Davis GJ et al.: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol.19(4),980–991 (2001).
  Medline CASGoogle Scholar
• 35  Bryant J: Toward a more rational selection of tailored adjuvant therapy [Poster presentation]. Presented at: 9th International St. Gallen Oncology Conference. St. Gallen, Switzerland, 26–29 January 2005.
  Google Scholar
• 36  Goldstein LJ, Gray R, Badve S et al.: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J. Clin. Oncol.26(25),4063–4071 (2008).
  MedlineGoogle Scholar
• 37  Habel L, Achacoso N, Maddala T et al.: Estrogen receptor and breast cancer survival in a Kaiser permanente population-based study: comparison of quantitative reverse transcriptase polymerase chain reaction and immunohistochemistry [Poster #5029]. Presented at: 30th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 13–16 December 2007.
  Google Scholar
• 38  Habel LA, Stanford JL: Hormone receptors and breast cancer. Epidemiol. Rev.15(1),209–219 (1993).
  Medline CASGoogle Scholar
• 39  Collins LC, Achacoso NA, Nekhlyudov L et al.: Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod. Pathol.20(11),1149–1155 (2007).
  MedlineGoogle Scholar
• 40  Haibe-Kains B, Desmedt C, Piette F et al.: Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics9,394 (2008).
  MedlineGoogle Scholar
• 41  Mook S, Schmidt MK, Viale G et al.: The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. PMID: 18661261 (2008) (Epub ahead of print).
  Google Scholar
• 42  Cardoso F, Saghatchian M, Thompson A, Rutgers E: Inconsistent criteria used in American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol.26(12),2058–2059; author reply 2060–2051 (2008).
  MedlineGoogle Scholar
• 43  de Azambuja E, Cardoso F, Meirsman L et al.: The new generation of breast cancer clinical trials: the right drug for the right target. Bull. Cancer95(3),352–357 (2008).
  Medline CASGoogle Scholar
• 44  Dinh P, Cardoso F, Sotiriou C, Piccart-Gebhart MJ: New tools for assessing breast cancer recurrence. Cancer Treat. Res.141,99–118 (2008).
  MedlineGoogle Scholar
• 45  Cardoso F, Van’t Veer L, Rutgers E et al.: Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol.26(5),729–735 (2008).
  MedlineGoogle Scholar
• 46  Widakowich C, de Azambuja E, Gil T et al.: Molecular targeted therapies in breast cancer: where are we now? Int. J. Biochem. Cell Biol.39(7–8),1375–1387 (2007).
  Medline CASGoogle Scholar
• 47  Bernard-Marty C, Cardoso F, Sotiriou C, Piccart MJ: Towards an individualization of systemic treatment of breast tumors. Bull. Cancer93(8),791–797 (2006).
  Medline CASGoogle Scholar
• 48  Buyse M, Loi S, van’t Veer L et al.: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst.98(17),1183–1192 (2006).
  Medline CASGoogle Scholar
• 49  Loi S, Sotiriou C, Buyse M et al.: Molecular forecasting of breast cancer: time to move forward with clinical testing. J. Clin. Oncol.24(4),721–722; author reply 722–723 (2006).
  MedlineGoogle Scholar
• 50  Colozza M, Azambuja E, Cardoso F et al.: Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Oncol.16(11),1723–1739 (2005).
  Medline CASGoogle Scholar
• 51  Cardoso F: Show me the genes – I will tell you who/how to treat! Breast Cancer Res.7(2),77–79 (2005).
  MedlineGoogle Scholar
• 52  Loi S, Desmedt C, Cardoso F, Piccart M, Sotiriou C: Breast cancer gene expression profiling: clinical trial and practice implications. Pharmacogenomics6(1),49–58 (2005).
  CASGoogle Scholar
• 53  Sparano J: The TAILORx trial: individualized options for treatment. Commun. Oncol.3(8),494–496 (2006).
  Google Scholar
• 54  Sparano J: Design of and Rationale for the Trial Assigning Individualized Options for Treatment (TAILORx). ASCO Educational Book, Alexandria, VA, USA (2007).▪ Description of the Program for the Assessment of Clinical Cancer Tests (PACCT) and TAILORx; the first trial that has been developed as a result of the PACCT program.
  Google Scholar
• 55  Sparano JA: TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer7(4),347–350 (2006).
  MedlineGoogle Scholar
• 101  NCCN Clinical Practice Guidelines in Oncology – Breast Cancer. National Comprehensive Cancer Network, V.2.2008, (2008) www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=I+Agree
  Google Scholar
• 102  Oncyotype DX: Breast Cancer Assay. Genomic Health, Inc. (2008) www.genomichealth.com/oncotype
  Google Scholar
• 103  Adjuvant! Online. Adjuvant! Inc. (2006) www.adjuvantonline.com/index.jsp
  Google Scholar
• 104  Clinical Trials PDQ: Phase III randomized study of adjuvant combination chemotherapy and hormonal therapy versus adjuvant hormonal therapy alone in women with previously resected axillary node-negative breast cancer with various levels of risk for recurrence (TAILORx trial) (2006) www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=472066&version=HealthProfessional&protocolsearchid=2329103
  Google Scholar